AXL mediates TRAIL resistance in esophageal adenocarcinoma
about
The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma.The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and AxlABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling.Cancer subclonal genetic architecture as a key to personalized medicine.
P2860
AXL mediates TRAIL resistance in esophageal adenocarcinoma
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
AXL mediates TRAIL resistance in esophageal adenocarcinoma
@ast
AXL mediates TRAIL resistance in esophageal adenocarcinoma
@en
type
label
AXL mediates TRAIL resistance in esophageal adenocarcinoma
@ast
AXL mediates TRAIL resistance in esophageal adenocarcinoma
@en
prefLabel
AXL mediates TRAIL resistance in esophageal adenocarcinoma
@ast
AXL mediates TRAIL resistance in esophageal adenocarcinoma
@en
P2860
P356
P1433
P1476
AXL mediates TRAIL resistance in esophageal adenocarcinoma
@en
P2093
Abbes Belkhiri
P2860
P304
P356
10.1593/NEO.122044
P577
2013-03-01T00:00:00Z